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Pathological angiogenesis and lymphangiogenesis 
have received increasing interest, mainly because 
of their presumed role in enhancing tumor   
progression  and  metastasis  (Carmeliet,  2003;   
Hirakawa  et  al.,  2005;  Karpanen  and  Alitalo, 
2008; Mumprecht and Detmar, 2009). However, 
vascular remodeling is also a hallmark of many 
inflammatory diseases such as chronic airway in-
flammation,  rheumatoid  arthritis,  inflammatory 
bowel disease, and the chronic inflammatory skin 
disease psoriasis (Detmar et al., 1994; Baluk et al., 
2005; Bainbridge et al., 2006; Danese et al., 2006). 
In these conditions, levels of vascular endothelial 
growth factor (VEGF) A are elevated in the in-
flamed tissue (Detmar et al., 1994; Koch et al., 
1994; Kanazawa et al., 2001). Homozygous   
keratin 14 (K14) VEGF-A transgenic (Tg) mice, 
which overexpress mouse VEGF-A164 in the epi-
dermis, spontaneously develop a chronic inflam-
matory skin disease with many features of human 
psoriasis at an age of 6 mo (Xia et al., 2003).   
In hemizygous K14-VEGF-A Tg mice, chronic 
inflammatory skin lesions can be induced by   
delayed-type hypersensitivity reactions (Kunstfeld   
et al., 2004), and we have previously used this 
model to discover that topical application of   
a small molecule inhibitor of VEGF receptor 
(VEGFR) kinases results in potent antiinflamma-
tory effects that were subsequently also found in 
other models of inflammation (Halin et al., 2008). 
Specific inhibition of VEGF-A also ameliorated 
psoriasis-like symptoms in a mouse model of pso-
riasis, where the epidermal specific deletion of   
c-Jun and JunB leads to the disease (Schonthaler   
et al., 2009). Together, these results indicate an 
important role of angiogenesis and blood vascular 
activation in sustaining chronic inflammation. 
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The role of lymphangiogenesis in inflammation has remained unclear. To investigate the 
role of lymphatic versus blood vasculature in chronic skin inflammation, we inhibited 
vascular endothelial growth factor (VEGF) receptor (VEGFR) signaling by function-blocking 
antibodies in the established keratin 14 (K14)–VEGF-A transgenic (Tg) mouse model of 
chronic cutaneous inflammation. Although treatment with an anti–VEGFR-2 antibody 
inhibited skin inflammation, epidermal hyperplasia, inflammatory infiltration, and angio-
genesis, systemic inhibition of VEGFR-3, surprisingly, increased inflammatory edema  
formation and inflammatory cell accumulation despite inhibition of lymphangiogenesis. 
Importantly, chronic Tg delivery of the lymphangiogenic factor VEGF-C to the skin of  
K14-VEGF-A mice completely inhibited development of chronic skin inflammation, epider-
mal hyperplasia and abnormal differentiation, and accumulation of CD8 T cells. Similar 
results were found after Tg delivery of mouse VEGF-D that only activates VEGFR-3 but  
not VEGFR-2. Moreover, intracutaneous injection of recombinant VEGF-C156S, which  
only activates VEGFR-3, significantly reduced inflammation. Although lymphatic drainage 
was inhibited in chronic skin inflammation, it was enhanced by Tg VEGF-C delivery.  
Together, these results reveal an unanticipated active role of lymphatic vessels in  
controlling chronic inflammation. Stimulation of functional lymphangiogenesis via  
VEGFR-3, in addition to antiangiogenic therapy, might therefore serve as a novel strategy 
to treat chronic inflammatory disorders of the skin and possibly also other organs.
© 2010 Huggenberger et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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chronic airway inflammation (Baluk et al., 2005). Moreover, 
lymphatic vessels have an increased density in arthritic joints of 
mice and men and are further increased after standard inflix-
imab therapy (Zhang et al., 2007; Polzer et al., 2008). In in-
flamed tissues, the lymphangiogenic factors VEGF-C and 
VEGF-A are secreted by immune cells such as macrophages 
and by resident tissue cells such as keratinocytes and fibroblasts. 
After  proteolytic  processing  of  the  propeptides,  the  mature 
VEGF-C also binds and activates VEGFR-2 which, besides its 
expression on the blood vascular endothelium, is also expressed 
In contrast, the role of the lymphatic vasculature in chronic in-
flammation has remained unclear.
It has been reported that the lymphatic vasculature plays   
an active role in corneal and kidney transplant rejection, in part 
by facilitating dendritic cell transport to draining lymph nodes 
(Cursiefen et al., 2004; Kerjaschki et al., 2004). In contrast, spe-
cific blockade of VEGFR-3, a receptor for the lymphangio-
genic growth factors VEGF-C and VEGF-D which is mainly 
expressed on the lymphatic endothelium in the adult (Kaipainen 
et al., 1995), increased edema formation in a mouse model of 
Figure 1.  Systemic inhibition of VEGFR-3 prolongs edema formation in chronic skin inflammation. (A) Hemizygous K14-VEGF-A Tg mice (n = 15) 
were painted at day 5 with 2% oxazolone and challenged at day 0 with 1% oxazolone on the ears. Starting at study day 7, the mice received a total  
of five i.p. injections of mAb DC101 (anti-mouse VEGFR-2), mF4-31C1 (anti-mouse VEGFR-3), or control rat IgG (n = 5 per group) every 3 d. Two indepen-
dent experiments were performed. (B) Treatment with mF4-31C1 () resulted in prolonged ear swelling, as compared with IgG-treated controls (e), 
whereas DC101 () treatment reduced the inflammatory ear swelling. Data represent mean ± SEM. (C) Hematoxylin and eosin (H&E) stains of mouse ears 
at day 21 after oxazolone challenge revealed increased edema formation, epidermal hyperthickening, and cell infiltration in the IgG-treated control group 
and after anti–VEGFR-3 mAb treatment, as compared with untreated wild-type mice (n = 3). Anti–VEGFR-2 mAb injection largely normalized skin archi-
tecture. One ear-half is shown. (D) Immunofluorescence stainings and quantification of BrdU+ cells show similar numbers of proliferating cells in the ear 
skin after anti–VEGFR-3 (R3) mAb treatment compared with IgG-injected mice. Systemic inhibition of VEGFR-2 (R2) significantly reduced the number of 
BrdU+ cells. Data represent mean ± SD. *, P < 0.05. ns, not significant. Bars, 100 µm.JEM VOL. 207, September 27, 2010 
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chronic skin inflammation. Unexpectedly, we also identified 
an important role of VEGF-C–induced lymphatic vessel acti-
vation in reducing the characteristic signs of cutaneous in-
flammation and in preventing the development of chronic 
inflammation. Importantly, the antiinflammatory effect of 
VEGF-C was seen both in a genetic mouse model with chronic 
overexpression of VEGF-C in the skin and after intracutane-
ous injection of recombinant VEGF-C protein. These studies, 
together with results in K14/VEGF-A/-D double Tg mice, 
also revealed that the antiinflammatory effects are mediated via 
activation of VEGFR-3. We hypothesize that stimulation of 
functional lymphangiogenesis—in addition to anti-angiogenic 
therapies—might represent a novel strategy to treat chronic in-
flammatory disorders of the skin or possibly also other chronic 
inflammatory diseases.
RESULTS
Systemic blockade of VEGFR-3 prolongs inflammatory 
edema formation
We first investigated the distinct roles of VEGFR-2 versus 
VEGFR-3 in chronic inflammation, using hemizygous K14-
VEGF-A Tg mice that develop chronic skin inflammation 
after sensitization and challenge with the contact sensitizer 
oxazolone (Kunstfeld et al., 2004). K14-VEGF-A Tg mice 
were painted with oxazolone (study day 5) and, 5 d later, 
on lymphatic vessels (Joukov et al., 1997; Kriehuber et al., 2001; 
Mäkinen et al., 2001b; Wirzenius et al., 2007).
We have recently found that lymphatic vessels are en-
larged in human psoriasis skin lesions and that lymphangio-
genesis is also a characteristic feature of the K14-VEGF-A 
chronic skin inflammation Tg mouse model (Kunstfeld et al., 
2004). Importantly, the K14-VEGF-A Tg mice are sensitive 
to standard antipsoriatic therapies, such as betamethasone, and 
they develop a Th17-like disease phenotype that is similar to 
human psoriasis (Hvid et al., 2008). In the present study,   
we used this model to investigate the individual contribution 
of the three VEGFRs to angiogenesis, lymphangiogenesis, 
and inflammation and the role of lymphatic vessels in chronic 
skin inflammation.
To this end, we first treated K14-VEGF-A Tg mice during 
the chronic phase of induced skin inflammation with block-
ing antibodies against VEGFR-1, -2, or -3, individually or in 
combination. In a second genetic approach, we established 
double Tg mice with overexpression of both VEGF-A and 
VEGF-C in the epidermis (K14-VEGF-A+C Tg mice), and 
also K14-VEGF-A/VEGF-D double Tg mice, and compared 
the course of induced skin inflammation in these mice with 
that observed in K14-VEGF-A single Tg mice. Overall, our 
studies reveal that VEGFR-2 is the main mediator of VEGF-A– 
induced pathological angiogenesis, lymphangiogenesis, and 
Figure 2.  Systemic inhibition of VEGFR-1 does not reduce chronic skin inflammation. (A) Hemizygous K14-VEGF-A Tg mice (n = 20) were 
painted and challenged as described in Fig. 1. Starting at study day 7, mice received five i.p. injections of mAb MF1 (anti–VEGFR-1, ), MF1 + DC101 
(anti-VEGFR-1+2, ), DC101 + mF4-31C1 (anti–VEGFR-2+3, ), or control rat IgG (e, n = 5 per group) every 3 d. Treatment with MF1 did not affect the 
chronic inflammatory response, whereas combined treatment with DC101 + MF1 and with DC101 + mF4-31C1 potently reduced skin inflammatory ear 
swelling. Data represent mean ± SEM. Two independent experiments were performed. (B) H&E stains of mouse ears at study day 21 after oxazolone chal-
lenge revealed edema formation, epidermal thickening, and inflammatory cell infiltration in the IgG control group and after anti–VEGFR-1 mAb treat-
ment. Anti–VEGFR-1+2 and anti–VEGFR-2+3 treatment largely normalized skin architecture. One ear half is shown. (C and D) Immunofluorescence 
stainings and quantification of BrdU+ cells show similar numbers of proliferating cells in the ear skin after anti–VEGFR-1 (R1, anti-R1) mAb treatment 
compared with control IgG-injected mice. Systemic inhibition of VEGFR-1+2 (R1+2, anti-R1+2) or VEGFR-2+3 (R2+3, anti-R2+3) reduced the number of 
BrdU+ cells. Data represent mean ± SD. *, P < 0.05. ns, not significant. Bars, 100 µm.2258 Lymphangiogenesis in chronic skin inflammation | Huggenberger et al.
and VEGFR-2+3 strongly reduced ear thickness (Fig. 2 A). 
At the histological level, skin sections of IgG-injected and 
anti–VEGFR-1 mAb–treated mice showed a comparable epi-
dermal hyperplasia and dermal inflammatory cell infiltration at 
21 d after oxazolone challenge. In contrast, anti–VEGFR-1+2– 
and –VEGFR-2+3–injected mice showed reduced thickening 
of the epidermis and decreased inflammatory cell infiltration 
(Fig. 2 B). After systemic blockade of VEGFR-1, there was 
no difference in the number of proliferating BrdU+ cells   
as compared with IgG injection (Fig. 2, C and D). In contrast, 
inhibition of VEGFR-1+2 or VEGFR-2+3 strongly reduced 
the number of proliferating cells by 65 or 71%, respec-
tively, as compared with IgG-treated mice (both P < 0.001;   
Fig. 2, C and D).
VEGFR-2 is the main mediator of VEGF-A–induced 
inflammatory angiogenesis
At 21 d after oxazolone challenge, the number of MECA-32+ 
cutaneous blood vessels per millimeter of epidermal basement 
membrane was increased by 316% in control IgG-treated K14-
VEGF-A Tg mice as compared with untreated wild-type mice, 
and blood vessel size was increased by 230% (Fig. S1 A). Sys-
temic inhibition of VEGFR-2, VEGFR-1+2, and VEGFR-2+3 
significantly reduced blood vessel number and size, whereas in-
hibition of VEGFR-1 or VEGFR-3 alone did not affect the 
blood vessel number or the blood vessel size (Fig. S1, A and B).
Because expression of VEGFR-3 has been previously de-
tected on some blood vessels associated with tumors and healing   
wounds (Valtola et al., 1999; Paavonen et al., 2000), we next   
were challenged on both sides of the ears by topical applica-
tion of oxazolone (Fig. 1 A). Starting at day 7 after challenge, 
the mice received five i.p. injections of either the inhibitory 
anti–VEGFR-2  mAb  DC101  or  the  anti–VEGFR-3  mAb 
mF4-31C1 every 3 d, whereas the control group received 
isotype-matched IgG. All mice were analyzed 2 d after the last 
antibody injection at study day 21 (Fig. 1 A).
Systemic inhibition of VEGFR-2 significantly reduced   
inflammatory ear swelling, as compared with control IgG- 
injected mice (Fig. 1 B). Surprisingly, blockade of VEGFR-3 
significantly prolonged the inflammatory ear swelling (Fig. 1 B). 
Ear tissue sections of control IgG injected mice showed the 
typical epidermal hyperplasia (acanthosis) and inflammatory cell 
infiltration at 21 d after oxazolone challenge, as compared with 
uninflamed wild-type mice (Fig. 1 C). The systemic inhibition 
of VEGFR-2, but not of VEGFR-3, diminished edema forma-
tion, epidermal hyperplasia, and inflammatory cell infiltration 
in the skin (Fig. 1 C). Inhibition of VEGFR-2 also reduced the 
number of proliferating cells by 44%, as compared with control 
IgG-treated mice (P < 0.05; Fig. 1 D), whereas no significant 
effect was seen after systemic blockade of VEGFR-3.
Systemic blockade of VEGFR-1 does not inhibit chronic  
skin inflammation
We next painted and challenged K14-VEGF-A Tg mice with 
oxazolone and inhibited either VEGFR-1 alone or VEGFR-1+2 
or VEGFR-2+3 in combination (Fig. 1 A). Systemic block-
ade of VEGFR-1 did not significantly change inflammatory 
ear swelling, whereas the combined inhibition of VEGFR-1+2 
Figure 3.  VEGFR-3 expression is restricted to lymphatic vessels in the inflamed skin of K14-VEGF-A Tg mice. (A) Differential immunofluores-
cence analyses for the blood vessel–specific marker MECA-32 (red) and for VEGFR-3 (green) revealed strong expression of VEGFR-3 by MECA-32–negative 
lymphatic vessels, whereas VEGFR-3 expression was largely absent on MECA-32–positive blood vessels. (B) CD11b+ cells (red) lack expression of VEGFR-3 
(green). Ear skin of IgG-injected K14-VEGF-A Tg mice at 21 d after oxazolone challenge is shown. The pictures shown are representative of five mice. Two 
independent experiments were performed. Bars, 100 µm.JEM VOL. 207, September 27, 2010 
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skin  of  K14-VEGF-A  Tg  mice  (Fig.  S2).  Anti–VEGFR-2 
treatment also resulted in a normalization of lymphatic vessel 
size, whereas the lymphatic vessels remained dilated in the 
anti–VEGFR-3–treated group (Fig. 4, A and B). The inhibi-
tion of VEGFR-1 did not affect the number of lymphatic ves-
sels but slightly increased their caliber (Fig. 4, A and B). Inhibition 
of VEGFR-1+2 and of VEGFR-2+3 in combination normal-
ized both the lymphatic vessel number and the lymphatic vessel 
size to the levels observed in normal uninflamed wild-type 
mice (Fig. 4, A and B).
We next used TaqMan-based real-time RT-PCR to in-
vestigate the levels of transcripts for the lymphangiogenic   
factors  VEGF-C  and  VEGF-D.  We  found  that  VEGF-C 
transcript levels were significantly increased by 38 ± 20% in 
the inflamed skin of IgG-injected mice at 21 d after oxazo-
lone challenge, as compared with uninflamed wild-type   
mice (P < 0.05), whereas VEGF-D levels were unchanged. 
These data indicate that VEGF-C levels are up-regulated in 
assessed VEGFR-3 expression on inflamed blood vessels.   
In agreement with the lack of blood vessel changes after anti–
VEGFR-3 treatment, we found that the expression of VEGFR-3 
was restricted to lymphatic vessels in the chronically inflamed 
skin of hemizygous K14-VEGF-A Tg mice (Fig. 3, A and B).
VEGFR-2 and -3 mediate VEGF-A–induced  
inflammatory lymphangiogenesis
Computer-assisted  morphometric  analyses  of  skin  sections, 
stained for the lymphatic-specific marker LYVE-1 at study day 21, 
revealed that lymphatic vessel number and lymphatic vessel size 
were increased by 171 and 251%, respectively, in the inflamed 
skin of control IgG-treated K14-VEGF-A Tg mice as compared 
with untreated wild-type mice (Fig. 4, A and B). Anti–VEGFR-3   
mAb treatment and, more efficiently, anti–VEGFR-2 treatment 
diminished the number of lymphatic vessels (Fig. 4, A and B). 
Importantly, we found that VEGFR-2 was expressed on lym-
phatic vessels in normal skin of wild-type mice and in inflamed 
Figure 4.  Inflammatory lymphangiogenesis is inhibited by blockade of VEGFR-2 or of VEGFR-3. (A) Quantitative image analyses of lymphatic 
vessels (LV; LYVE-1+, green) revealed a significantly increased number and size of lymphatic vessels in control IgG injected mice at day 21 after induction 
of inflammation, as compared with normal wild-type (wt) mice. The mean number of lymphatic vessels was reduced after anti–VEGFR-2 (R2) and after 
anti–VEGFR-3 (R3) treatment but not after systemic inhibition of VEGFR-1 (R1). Combined inhibition of VEGFR-1+2 (1+2) or VEGFR-2+3 (2+3) also re-
duced lymphatic vessel numbers. Systemic inhibition of VEGFR-2, VEGFR-1+2, and VEGFR-2+3 resulted in a reduced mean size of lymphatic vessels.  
n = 5 mice per group. Two independent experiments were performed. Data represent mean ± SD. ‡, P < 0.05 versus wild-type; *, P < 0.05 versus IgG.  
ns, not significant. (B) Representative images of LYVE-1 immunostains (green) are shown. Bars, 100 µm.2260 Lymphangiogenesis in chronic skin inflammation | Huggenberger et al.
interfollicular epidermis and largely restricted to keratinocytes 
of the outer root sheath of the hair follicle (Fig. 5 A), which   
is in agreement with previous studies (Stark et al., 1987).   
Loricrin, a marker of terminal epidermal differentiation, was 
restricted to the upper granular layer in uninflamed mouse skin 
(Fig. 5 B). In contrast, in the inflamed skin of control IgG-treated 
mice, keratin 6 and loricrin showed a much broader epidermal 
staining pattern. After systemic inhibition of VEGFR-1 or 
VEGFR-3, the expression pattern of keratin 6 (Fig. 5 A) and   
inflamed skin, and they also suggest that lymphangiogenesis 
in the K14-VEGF-A mouse model of psoriasis is predomi-
nantly dependent on VEGF-A/VEGFR-2 signaling with a 
partial contribution of VEGF-C/VEGFR-3 signaling.
Inhibition of VEGFR-2 decreases inflammatory cell 
infiltration and normalizes epidermal differentiation
In ear sections of normal wild-type mice, the hyperprolifera-
tion-associated keratin 6 was faintly expressed in the normal 
Figure 5.  Systemic blockade of VEGFR-2 results in normalized epidermal differentiation and reduced inflammatory skin infiltration.  
(A and B) Immunofluorescence analyses of ear skin sections from normal wild-type mice show that the hyperproliferation-associated keratin 6 is only faintly 
expressed in the normal interfollicular epidermis and is largely restricted to the hair follicle (A). Loricrin, a marker of terminal epidermal differentiation, is restricted 
to the upper granular layer in normal mouse skin (B). At day 21 of chronic skin inflammation in control IgG-treated mice, keratin 6 and loricrin show a much  
broader expression pattern. Inhibition of VEGFR-2 (anti-R2), alone or in combination with inhibition of VEGFR-1 or VEGFR-3, largely normalized keratin 6 and 
loricrin expression patterns. Treatment with anti–VEGFR-1 or anti–VEGR-3 showed no major effect. (C and E) CD11b+ cells are rarely found in normal mouse  
skin (wt). The number of CD11b+ cells was increased in the inflamed skin of control IgG-treated mice and was decreased after the inhibition of VEGFR-2,  
VEGFR-1+2, or VEGFR-2+3 but not after inhibition of VEGFR-1. Inhibition of VEGFR-3 resulted in enhanced numbers of CD11b+ cells. (D and E) Inhibition of 
VEGFR-2, VEGFR-1+2, and VEGFR-2+3 strongly decreased the number of intraepidermal CD8+ T-lymphocytes, whereas the inhibition of VEGFR-1 or VEGFR-3 had 
no effect, as compared with IgG-treated mice. Bars, 100 µm. (E) Computer-assisted quantification of the numbers of CD11b+ and CD8+ cells per millimeter of  
epidermal basement membrane. n = 5 mice per group. Two independent experiments were performed. Data represent mean ± SD. *, P < 0.05. ns, not significant.JEM VOL. 207, September 27, 2010 
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anti–VEGFR-1+2, and anti–VEGFR-
2+3 mAb injections, resulted in signif-
icant downmodulation of VEGFR-1 and VEGFR-2 mRNA 
expression (Fig. 6).
The IL-23–TH17 axis is important in the development of 
many human inflammatory diseases including psoriasis (Louten 
et al., 2009). It was recently shown—by a genome wide scan—
that human psoriasis is associated with the IL-23 pathway (Nair 
et al., 2009) and that the fully human monoclonal antibody 
ustekinumab, which specifically inhibits the p40 subunit of the 
IL-12 and IL-23 cytokines, might be an effective treatment   
for psoriasis (Krueger et al., 2007). Using TaqMan-based real-
time RT-PCR analyses, we found a strong up-regulation 
(8.2–8.3-fold) of the gene expression of the IL-23–specific 
subunit p19 (IL-23a) in the inflamed skin of IgG-injected 
mice, compared with uninflamed wild-type mice (Fig. 6). 
Specific  inhibition  of  VEGFR-1+2  significantly  decreased 
IL-23a expression, and anti–VEGFR-2 and anti–VEGFR-2+3 
showed a tendency of reduced IL-23a expression (P = 0.057 
and 0.12, respectively; Fig. 6). In contrast, single anti–VEGFR-1 
and anti–VEGFR-3 treatments showed no effect.
Tg overexpression of VEGF-C in the skin of VEGF-A Tg mice 
resolves chronic skin inflammation
Because  blockade  of  VEGFR-3  reduced  the  number  of 
lymphatic vessels and also prolonged the course of inflam-
matory ear swelling, we next investigated whether enhanced 
cutaneous levels of the VEGFR-3 ligand VEGF-C might 
modulate skin inflammation. To this end, we crossed ho-
mozygous VEGF-A Tg mice with hemizygous VEGF-C 
Tg mice to obtain VEGF-A+C double Tg mice and single 
VEGF-A Tg littermates. VEGF-C Tg mice overexpress 
human VEGF-C under the K14 promoter and have increased 
numbers of lymphatic vessels in their skin with no obvious 
effect on the blood vessel phenotype (Jeltsch et al., 1997). 
Surprisingly, chronic Tg overexpression of VEGF-C in the 
K14-VEGF-A Tg mice had already potently reduced ear 
loricrin (Fig. 5 B) remained largely unchanged. In contrast, inhi-
bition of VEGFR-2 and, more potently, of VEGFR-1+2 or 
VEGFR-2+3, reverted keratin 6 and loricrin expression to a 
pattern seen in normal wild-type mice (Fig. 5, A and B).
CD11b+ cells are rarely found in normal mouse skin 
(Fig. 5 C) and CD8+ T lymphocytes are almost completely 
absent from the epidermis (Fig. 5 D). In human psoriasis and in 
the K14-VEGF-A Tg mouse model, there is a strong infiltra-
tion of CD11b+ cells into the dermis and of CD8+ T lympho-
cytes into the epidermis (Fig. 5, C and D). Unexpectedly, the 
number of CD11b+ cells within the inflamed skin significantly 
increased after inhibition of VEGFR-3. After inhibition of 
VEGFR-2, VEGFR-1+2, and VEGFR-2+3, the number of 
CD11b+  cells  was  significantly  reduced,  whereas  inhibition   
of VEGFR-1 had no effect (Fig. 5, C and E). Similarly, the   
inhibition of VEGFR-2, VEGFR-1+2, and VEGFR-2+3 
strongly  decreased  the  number  of  intraepidermal  CD8+  
T-lymphocytes, whereas the inhibition of VEGFR-1 or 
VEGFR-3 had no effect (Fig. 5, D and E).
We next performed real-time RT-PCR analyses of mouse 
ear skin extracts for the expression of all three VEGFRs 
after treatment for 14 d. At study day 21, there was a sig-
nificantly  increased  expression  of  VEGFR-1  (3.5–4.3- 
fold), VEGFR-2 (3.7–4.1-fold), and VEGFR-3 (1.4–1.6-fold) 
in the inflamed skin of control IgG-injected VEGF-A Tg 
mice, as compared with uninflamed wild-type mice (Fig. 6), 
which is in agreement with the observed induction of in-
flammatory angiogenesis and lymphangiogenesis. Consistent 
with the lack of effects on blood vessel angiogenesis seen in 
the immunofluorescence analyses, anti–VEGFR-1 and anti–
VEGFR-3 mAb treatment did not result in a reduction of 
VEGFR-1  and  -2  mRNA  transcript  levels.  However,   
systemic inhibition of VEGFR-3 resulted in a significant 
down-regulation of VEGFR-3 expression. Effective anti-
inflammatory treatment strategies, such as anti–VEGFR-2, 
Figure 6.  Expression of VEGFR and  
IL-23a mRNA after antibody injections. 
TaqMan-based real-time RT-PCR analyses 
were performed on whole ear skin extracts 
after 14 d of antibody treatment (study  
day 21) in K14-VEGF-A Tg mice. VEGFR-1,  
VEGFR-2, VEGFR-3, and the IL-23–specific 
subunit p19 (IL-23a) were significantly up-
regulated in inflamed IgG-injected mouse  
skin compared with untreated wild-type  
mice. The modulation of mRNA transcript 
levels after the corresponding antibody injec-
tions is shown. n = 5 mice per group. Two 
independent experiments were performed. 
Data represent mean ± SD. ‡, P < 0.05  
versus wild type; *, P < 0.05 versus IgG. R1, 
anti–VEGFR-1; R2, anti–VEGFR-2; R3, anti–
VEGFR-3; 1+2, anti–VEGFR-1+2; 2+3, anti–
VEGFR-2+3 antibody-injected mice.2262 Lymphangiogenesis in chronic skin inflammation | Huggenberger et al.
thickness 2 d after oxazolone challenge, which led to a com-
plete resolution of skin inflammation by day 28, whereas 
VEGF-A single Tg mice developed a chronic skin inflam-
mation (Fig. 7 A).
Histological analyses of ear sections at day 28 revealed 
normalization of the skin architecture in VEGF-A+C dou-
ble Tg mice (Fig. 7 B), which is similar to the uninflamed 
skin of control mice (Fig. 1 C), whereas VEGF-A single Tg 
mice showed the classical signs of epidermal hyperplasia 
and inflammatory cell infiltration (Fig. 7 B). Double im-
munofluorescence analyses of CD31+/LYVE-1+ lymphatic 
vessels showed an increased density of lymphatic vessels in 
the skin of VEGF-A+C double Tg mice at day 28, as com-
pared with VEGF-A single Tg mice (Fig. 7, C and E). Although 
VEGF-A  single  Tg  mice  showed  enlarged  and  tortuous 
CD31+/LYVE-1 blood vessels, the blood vascular pheno-
type was largely normal in the VEGF-A+C double Tg mice 
(Fig. 7 C). Computer-based image analyses revealed that 
the blood vessel number and size (Fig. 7 D) were sig-
nificantly lower in the VEGF-A+C double Tg mice than 
in the VEGF-A single Tg mice. In contrast, no differences 
were  observed  under  noninflamed  baseline  conditions 
(Fig. S4, A and B).
The VEGF-A level is a good marker for inflammation in 
human psoriasis and in the K14-VEGF-A mouse model of 
chronic skin inflammation (Bhushan et al., 1999; Kunstfeld   
et al., 2004; Halin et al., 2007, 2008). In agreement with an 
overall improvement of inflammation, VEGF-A protein lev-
els were significantly lower (P < 0.05) in VEGF-A+C mice 
than in VEGF-A Tg mice (Fig. 7 F) at day 28, whereas the 
VEGF-A protein levels were similar in the normal/nonpsoriatic 
skin of both types of mice (5.1 ± 1.0 pg/mg for VEGF-A vs. 
4.8 ± 0.6 pg/mg for VEGF-A+C Tg mice; P > 0.05).
Figure 7.  Chronic Tg overexpression of VEGF-C in the skin of 
K14-VEGF-A Tg mice prevents chronic skin inflammation.  
(A) K14-VEGF-A Tg mice (VEGF-A; n = 5) and K14-VEGF-A+C double Tg mice 
(VEGF-A+C; n = 5) were painted and challenged using oxazolone as de-
scribed in Fig. 1. Ear thickness was measured over 28 d. Inflammatory ear 
swelling was significantly reduced in VEGF-A+C double Tg mice, as com-
pared with VEGF-A Tg mice. Importantly, ear thickness of VEGF-A+C Tg 
mice went back to normal levels within 4 wk. Data represent mean ± SEM. 
(B) H&E-stained sections revealed reduced edema formation, epidermal 
thickening, and inflammatory cell infiltration in K14-VEGF-A+C double Tg 
mice as compared with K14-VEGF-A mice at day 28 after oxazolone chal-
lenge. (C) At day 28, differential immunofluorescence stains for lymphatic 
vessels (CD31+/LYVE-1+; green) and blood vessels (CD31+/LYVE-1; red) 
revealed that K14-VEGF-A+C mice have a strong increase in their lym-
phatic vessel network compared with K14-VEGF-A Tg mice. Bars, 100 µm. 
(D and E) At day 28 after oxazolone challenge, computer-assisted image 
analyses revealed a significantly reduced number and mean size of blood 
vessels (BV; D) and an increased density of lymphatic vessels (LV; E) in the 
K14-VEGF-A+C (A+C) double Tg mice compared with K14-VEGF-A (A) Tg 
mice. (F) ELISA analyses of ear lysates showed decreased levels of VEGF-A 
in double Tg K14-VEGF-A+C mice compared with K14-VEGF-A Tg mice at 
28 d after oxazolone challenge. Two independent experiments were per-
formed. Data represent mean ± SD. *, P < 0.05. ns, not significant.
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Fig. S5 and Fig. S6. 
2  d  after  oxazo-
lone challenge, the 
lymph  flow  from 
the lymph node to 
efferent lymphatic vessels was similar to the uninflamed state, 
as indicated by the half-life time of dye fluorescence intensity 
in the lymph node (4.42 ± 1.95 vs. 2.78 ± 0.55 min; P > 0.05; 
Fig. 9 A). The lymph flow was decreased at day 7 and was sig-
nificantly reduced at day 14 after oxazolone challenge, as   
compared with uninflamed K14-VEGF-A Tg mice, indicating 
dysfunction of the lymphatic vasculature during chronic skin 
inflammation (Fig. 9 A). Importantly, the lymph flow was 
significantly enhanced in the K14-VEGF-A+C double Tg 
mice at day 14 after induction of inflammation, as compared 
with the K14-VEGF-A single Tg mice (Fig. 9 B). These data 
suggest that increased VEGF-C–induced lymphatic flow might 
contribute to resolving chronic skin inflammation in the K14-
VEGF-A+C double Tg mice.
To further investigate whether the antiinflammatory effect 
of Tg overexpression of VEGF-C (which might bind both 
VEGFR-3 and VEGFR-2) was indeed mediated via VEGFR-3 
activation on lymphatic endothelium in the skin, we next es-
tablished a new Tg mouse model with chronic Tg overexpres-
sion of mouse VEGF-D in the skin of K14-VEGF-A Tg mice. 
In contrast to VEGF-C, mouse VEGF-D is a specific ligand for 
VEGFR-3 but not for VEGFR-2 (Baldwin et al., 2001). Sen-
sitization and challenge with oxazolone of K14-VEGF-A sin-
gle Tg mice resulted in chronic skin inflammation, whereas 
K14-VEGF-A+D double Tg mice showed a significantly re-
duced ear thickness, similar to what we observed in the K14-
VEGF-A+C double Tg mice (Fig. 10 A).
VEGF-A/-C and VEGF-A/-D double Tg mice show 
chronically elevated levels of VEGF-C or VEGF-D in the 
skin and, thus, an increase in the number of preexisting lym-
phatic vessels before the induction of inflammation might 
have contributed to the inhibition of chronic inflammation. 
Thus, we next investigated whether acute delivery of VEGF-C 
to the skin might also ameliorate cutaneous inflammation.   
Genetic overexpression of VEGF-C in the skin of VEGF-A Tg 
mice decreases inflammatory cell infiltration and normalizes 
epidermal architecture
At day 28, the hyperproliferation-associated marker keratin 6 
was almost absent in the epidermis of VEGF-A+C double Tg 
mice and restricted to the hair follicle, similar to the findings 
in normal uninflamed wild-type mice, but was still present in 
the VEGF-A single Tg mice (Fig. 8 A and Fig. 5 A). The ex-
pression of the differentiation marker loricrin was restricted 
to the upper granular layer in the VEGF-A+C double Tg 
mice but not in VEGF-A single Tg mice, with a pattern very 
similar to that of uninflamed wild-type mice (Fig. 8 A and 
Fig. 5 B). Importantly, there was no baseline difference under 
noninflamed conditions (Fig. S4 A).
Genetic overexpression of VEGF-C in the skin of VEGF-A 
Tg mice also strongly reduced the number of CD11b+ mono-
cytes/granulocytes in the dermis and of CD8+ T-lymphocytes 
in the epidermis, as compared with VEGF-A single Tg mice 
(Fig. 8, B and C). Using a quantitative cytokine array, our pre-
liminary data indicate that the protein levels of IL-17, IL-1, 
M-CSF, and MCP-1 were significantly lower in the double 
Tg VEGF-A+C mice than in single VEGF-A Tg mice. TNF, 
IFN-, IL-12, and IL-1 levels were also lower in the   
skin of VEGF-A+C double Tg mice than in VEGF-A Tg 
mice (Fig. S3).
Chronic skin inflammation in K14-VEGF-A mice is 
associated with impaired lymphatic function
Because K14-VEGF-A+C double Tg mice were characterized 
by reduced skin inflammation, we next asked if dysfunction of 
lymphatic vessels might contribute to the chronic skin inflam-
mation in the K14-VEGF-A mouse model. We performed   
in vivo near-infrared imaging of lymphatic drainage using the 
IVIS system. We injected indocyanine green–containing lipo-
somes into the ear skin of K14-VEGF-A Tg mice and assessed 
the fluorescent signal in the draining superficial parotid lymph 
node (Van den Broeck et al., 2006) over a time course of 25 min. 
The positioning of the mice, a representative image of a fluores-
cently labeled lymph node, and the data analysis are shown in 
Figure 8.  Tg overexpression of VEGF-C 
in the skin of K14-VEGF-A Tg mice re-
duces inflammatory cell infiltration and 
normalizes epidermal proliferation and 
differentiation. (A) Immunofluorescence 
analyses revealed that the hyperproliferation 
marker keratin 6 was restricted to hair fol-
licles, and that the differentiation marker 
loricrin was restricted to the suprabasal layers 
of the epidermis in the K14-VEGF-A+C Tg 
mice, whereas both keratin 6 and loricrin  
were broadly expressed in the epidermis of 
K14-VEGF-A Tg mice. Bars, 100 µm.  
(B and C) Quantitative image analyses of ear 
skin sections at study day 28 revealed signifi-
cantly reduced numbers of dermal CD11b+ 
monocytes/granulocytes (B) and intraepider-
mal CD8+ T cells (C) in K14-VEGF-A+C double 
Tg mice compared with K14-VEGF-A single Tg 
mice. n = 5 per group. Two independent ex-
periments were performed. Data represent 
mean ± SD. *, P < 0.05.2264 Lymphangiogenesis in chronic skin inflammation | Huggenberger et al.
DISCUSSION
In this paper, we have investigated the individual role of the 
three VEGFRs and of lymphatic vessels in a VEGF-A–driven 
mouse model of chronic skin inflammation. To this end, we 
used pharmacological approaches to analyze the effect of   
specific inhibition of VEGFR signaling on chronic skin in-
flammation and we also applied genetic approaches by estab-
lishing new mouse models for the chronic Tg delivery of 
both VEGF-C and VEGF-A, or of both mouse VEGF-D and 
VEGF-A, under control of the K14 promoter. We found that 
systemic inhibition of angiogenesis by blockade of VEGFR-2 
significantly ameliorated the course of cutaneous inflammation, 
whereas  inhibition  of  VEGFR-3  prolonged  inflammatory 
edema  formation  despite  inhibition  of  lymphangiogenesis. 
To our knowledge, this is the first study which shows that 
specific activation of lymphatic vessels by Tg overexpression 
of VEGF-C or the VEGFR-3–specific ligand mVEGF-D, or 
by the injection of the VEGFR-3–specific mutant VEGF-
C156S, inhibits chronic inflammation.
Most of the major parameters of psoriasis skin lesions,   
including epidermal hyperproliferation and impaired dif-
ferentiation, pathological angiogenesis, inflammatory cell 
infiltration with accumulation of CD4 cells in the dermis and 
CD8 cells in the epidermis, and the expression of IL-23a, 
In particular, we were interested whether specific activation 
of VEGFR-3 might inhibit inflammation. To this end, we 
injected recombinant VEGF-C156S protein, a VEGFR-3– 
specific mutant which does not activate VEGFR-2 (Joukov   
et al., 1998), daily into the inflamed ear skin of K14-VEGF-A 
Tg mice during the chronic phase of skin inflammation, 
starting at day 7 after oxazolone challenge. Already after   
5 d of VEGF-C156S therapy, ear swelling was significantly 
reduced, as compared with PBS-injected controls (Fig. 10 B). 
The antiinflammatory effect was maintained until the end 
of the treatment at day 21 (Fig. 10 B). Although there were 
no major changes of lymph flow (unpublished data), histo-
logical analyses revealed a significantly reduced blood ves-
sel size (282 ± 44 vs. 373 ± 82 µm2; P < 0.05), increased 
lymphatic vessel size (1064 ± 303 vs. 677 ± 169 µm2; P < 0.05), 
and increased area covered by lymphatic vessels (11.8 ± 
2.8 vs. 6.6 ± 0.7%; P < 0.05) after injection of VEGF-
C156S as compared with PBS injection. The number of 
blood or lymphatic vessels was not different between the 
two groups. Furthermore, the number of CD11b+ cells 
was significantly decreased after intradermal injections of 
VEGF-C156S  as  compared  with  PBS  (39  ±  9  [VEGF-
C156S] vs. 63 ± 10 [PBS] cells/mm epidermal basement 
membrane; P < 0.05).
Figure 9.  Lymphatic vessel drainage function is impaired 
during chronic skin inflammation and is enhanced by Tg 
overexpression of VEGF-C. (A) K14-VEGF-A Tg mice (n = 4) 
were sensitized and challenged using oxazolone. Indocyanine 
green–containing liposomes were injected intradermally into the 
ear skin, and the lymphatic drainage from the superficial parotid 
lymph node was monitored in vivo using the Xenogen IVIS sys-
tem over a period of 25 min. The lymph flow was unaltered at 2 d 
after induction of skin inflammation, as compared with normal 
skin (Pre), but progressively declined until day 14, as indicated by 
the significantly increased half-life time. An exponential decay 
model was used to calculate half-life times. Two independent 
experiments were performed. Horizontal bars indicate mean.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) K14-VEGF-A (n = 4) and K14-VEGF-A+C (n = 4) Tg mice were treated as described in A, and indocyanine green–
containing liposomes were injected intradermally at 14 d after oxazolone challenge. The lymphatic flow from the lymph node was significantly higher in 
the K14-VEGF-A+C double Tg mice than in the K14-VEGF-A single Tg mice, as indicated by the significantly shorter half-life time. Two independent  
experiments were performed. Data represent mean ± SD. *, P < 0.05.
Figure 10.  Specific activation of VEGFR-3 
reduces inflammatory ear swelling in  
the K14-VEGF-A mouse model. (A) Hemi-
zygous K14-VEGF-A+D (, n = 5) and K14-
VEGF-A (, n = 5) Tg mice were painted at 
day 5 with 2% oxazolone and challenged at 
day 0 with 1% oxazolone on the ear skin.  
(B) K14-VEGF-A Tg mice (n = 11) were treated 
as described in A. Starting at study day 7, the 
mice received daily intradermal injections of 
200 ng of recombinant VEGF-C156S protein 
(, n = 6), a VEGFR-3–specific mutant, or of 
PBS (, n = 5) for 14 d. Two independent 
experiments were performed. Data represent 
mean ± SEM. *, P < 0.05.JEM VOL. 207, September 27, 2010 
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binding compared with the homodimeric receptor situation 
(Dixelius et al., 2003).
Inflammation-induced lymphangiogenesis can be regu-
lated by direct VEGF-A/VEGFR-2 and by VEGF-C/VEGF-D/
VEGFR-3 signaling and might be modulated by the attrac-
tion of inflammatory cells releasing lymphangiogenic factors   
(Baluk et al., 2005; Kataru et al., 2009; Wuest and Carr, 2010). 
However, VEGF-A–induced lymphatic vessels might be less 
functional  than  those  induced  by  VEGF-C  or  VEGF-D/
VEGFR-3 signaling (Nagy et al., 2002; Kajiya et al., 2006), 
although one has to keep in mind that mouse VEGF-A164 
and the human isoform VEGF-A165 likely transduce different 
signals in lymphatic vessels in vivo (Wirzenius et al., 2007). 
Our findings indicate that lymphangiogenesis in the K14-
VEGF-A mouse model of psoriasis is mainly dependent on 
VEGFR-2 but that VEGFR-3 signaling partially participates 
in driving lymphangiogenesis. This is mainly caused by the 
lymphangiogenic factor VEGF-C, which was up-regulated 
during  chronic  skin  inflammation.  Interestingly,  a  recent 
publication on HSV-1–infected cells found that VEGF-A is 
the sole inductor of corneal lymphangiogenesis (Wuest and 
Carr, 2010).
Overall, our VEGFR blocking studies revealed that in-
hibition of angiogenesis is sufficient to resolve chronic skin in-
flammation. In contrast, specifically reducing inflammatory 
lymphangiogenesis by inhibition of VEGFR-3 delayed edema 
resolution. It is likely that the increased edema observed after 
specific blockade of VEGFR-3 is a result of improper lym-
phatic drainage. It has recently been shown that the inhibition 
of VEGF-C/-D by sVEGFR-3 significantly decreased lymph 
flow in a model of bacterial skin inflammation (Kataru et al., 
2009), that genetic overexpression of soluble VEGFR-3 in   
the skin of mice resulted in a lymphedema-like phenotype 
(Mäkinen et al., 2001a), and that the inhibition of VEGFR-3 
decreased lymph flow in a mouse model of chronic inflamma-
tory arthritis (Guo et al., 2009). Importantly, both of the latter 
models are strongly TNF dependent. Conversely, application 
of VEGF-C or tumor-derived VEGF-C have been found to 
enhance lymphatic function and flow, respectively (Karkkainen 
et al., 2001; Szuba et al., 2002; Yoon et al., 2003; Hoshida   
et al., 2006; Tammela et al., 2007). The impaired lymphatic 
drainage might also explain the accumulation of CD11b+  
cells that we observed after blockade of VEGFR-3. Interest-
ingly, the CD11b+ cells in the skin lacked the expression of 
VEGFR-3, unlike the CD11b+ cells in the inflamed cornea 
which have been reported to uniformly express VEGFR-3 
(Hamrah et al., 2004).
Our  study  reveals  that  the  lymphatic  vessels  become   
dysfunctional during the establishment of chronic inflamma-
tory skin lesions and that lymphatic function can be restored 
by genetically overexpressing VEGF-C. We assessed the lymph 
flow at study day 14, when the skin inflammation in the 
K14-VEGF-A mouse model reaches the most chronic state 
and when ear thickness remains largely constant (Fig. 7 A). 
We unexpectedly found that the half-life time of dye dis-
appearance from the ear-draining superficial parotid lymph 
were also found in the K14/VEGF-A Tg model and were 
largely normalized after specific inhibition of angiogenesis   
or  specific  stimulation  of  lymphangiogenesis.  Importantly, 
we found that the chronic inflammation in the K14-VEGF-A 
mouse model is accompanied by impaired lymphatic vessel 
function and that Tg delivery of VEGF-C to the skin restores 
the lymphatic vessel function in this model. Together, these 
findings surprisingly indicate that stimulation of lymphangio-
genesis and reversion of lymphatic vessel dysfunction, which 
is primarily mediated through VEGF-A in this model system 
(Kajiya et al., 2006), might be sufficient to resolve chronic 
skin inflammation.
The receptor tyrosine kinase VEGFR-2 is thought to be 
the main mediator of VEGF-A–driven endothelial cell prolif-
eration,  differentiation,  and  sprouting  (Adams  and  Alitalo, 
2007). This is consistent with our data showing potent anti-
angiogenic effects after blockade of VEGFR-2 in chronic in-
flammation induced in K14/VEGF-A Tg mice. In contrast, 
short-term inhibition of VEGFR-2 in an acute delayed-type 
hypersensitivity model in wild-type mice did not ameliorate 
acute skin inflammation (Kunstfeld et al., 2004).
The expression of VEGFR-3 has been generally thought 
to be restricted to the lymphatic vascular system, with some 
exceptions (Partanen et al., 2000; Hamrah et al., 2003), and 
the biological effects of inhibition of VEGFR-3 have been at-
tributed to its effects on activated lymphatic vessels (Pytowski 
et al., 2005). Recently, it has been reported that VEGF-A in-
duces the expression of VEGFR-3 on angiogenic sprouts dur-
ing embryonic development and also in distinct pathological 
settings (Tammela et al., 2008). Our current findings reveal 
that in the setting of chronic skin inflammation in mice, the 
tortuous cutaneous blood vessels, in the vicinity of the VEGF-A– 
secreting epidermis, lack expression of VEGFR-3, as com-
pared with the strong VEGFR-3 expression detected on 
MECA32-negative lymphatic vessels. These findings likely 
explain why we did not detect any major effects of VEGFR-3 
blockade on the cutaneous blood vasculature, as assessed his-
tologically and by measuring the expression levels of all three 
VEGFRs. These findings also indicate that specific activation 
of VEGFR-3 in inflamed skin should not promote skin an-
giogenesis. Indeed, we did not find any further induction of 
blood vessel angiogenesis in the skin of VEGF-A/VEGF-D 
double Tg mice, as compared with VEGF-A single Tg mice.
Although the single inhibition of VEGFR-1 did not ame-
liorate inflammation or angiogenesis, and VEGFR-3 blockade 
prolonged inflammation, the combined blockade of VEGFR-
1+2 and VEGFR-2+3 showed even more pronounced in-
hibitory effects than the single inhibition of VEGFR-2 on all 
parameters analyzed. This might be explained by a role of   
heterodimerization of the VEGFRs in modulating the signal-
ing cascade. VEGF-E, which specifically activates VEGFR-2, 
induces angiogenesis without signs of edema and hemorrhag-
ing (Kiba et al., 2003). This finding shows that VEGFR-1/-2 
cross talk might be required for driving vascular permeability. 
Additionally, heterodimerization of VEGFR-3 with VEGFR-2 
results in a different use of phosphorylation sites upon ligand 2266 Lymphangiogenesis in chronic skin inflammation | Huggenberger et al.
(4-ethoxymethylene-2  phenyl-2-oxazoline-5-one;  Sigma-Aldrich)  in   
acetone/olive oil (4:1 vol/vol) was applied topically to the shaved abdomen   
(50 µl) and to each paw (5 µl). 5 d after sensitization (day 0), both ears were 
challenged by topical application of 10 µl oxazolone (1%) on each side. Ear 
thickness was measured before challenge and repeatedly after challenge using 
calipers. Total ear thickness was measured as readout of inflammation. Start-
ing on day 7, 800 µg of a blocking rat anti–mouse VEGFR-1 mAb (MF1), 
rat anti–mouse VEGFR-2 (DC101), rat anti–mouse VEGFR-3 mAb (mF4-
31C1; all from Imclone Systems Inc.), 800 µg each of MF1 + DC101, 800 µg 
each of DC101 + mF4-31C1, or control rat IgG (Sigma-Aldrich) was ad-
ministered i.p. to K14-VEGF-A Tg mice for 14 d every third day (n = 5 per 
group). This dosage was previously shown to efficiently inhibit VEGFR sig-
naling in vivo (Baluk et al., 2005). On day 21, mice were injected with 300 µl 
PBS containing 40 mM BrdU (Sigma-Aldrich). After 2.5 h, mice were 
killed and one ear was embedded in optimal cutting temperature (OCT) 
compound (Sakura). The other ear was stored in RNALater solution   
(Applied Biosystems).
In additional experiments, K14-VEGF-A+C (n = 9) and K14-VEGF-
A+D (n = 5) double Tg mice and their single Tg K14-VEGF-A littermates 
(n = 14) were treated with oxazolone as indicated in the previous paragraph. 
The ears were analyzed at study day 28. All experiments were performed at 
least twice.
In addition, hemizygous K14-VEGF-A Tg mice were treated for 2 wk, 
starting on study day 7 (after oxazolone challenge) by daily intradermal injec-
tions (into the ear skin) with 200 ng of recombinant VEGF-C (Cys156Ser; 
R&D Systems) dissolved in 1 µl PBS (n = 6) using a Hamilton syringe. The 
control group was injected with PBS alone (n = 5).
Immunohistology. On study day 21 or 28, respectively, mice were killed 
and their ears were collected. Tissues were embedded in OCT compound, 
frozen on dry ice, and 7-µm cryostat sections were cut. Specimens were 
placed on glass slides, air dried, and fixed with acetone for 2 min at 20°C. 
After rehydration with 80% methanol at 4°C, PBS, and PBS with 12% BSA, 
the specimens were incubated with the respective antibodies. Standard H&E 
stainings were performed, and immunofluorescence was performed as previ-
ously described (Kunstfeld et al., 2004; Halin et al., 2008) using the follow-
ing  antibodies:  anti–mouse  LYVE-1  (AngioBio),  biotin  anti–MECA-32, 
anti–mouse CD31 (both from BD), anti–BrdU–Alexa Fluor 594 (Invitro-
gen), anti–mouse VEGFR-2 (AF644), anti–mouse VEGFR-3 (AF743; both 
R&D Systems), anti–mouse keratin 6, loricrin (both from Covance Research 
Products), biotin anti–mouse CD11b, and CD8 (BD). Cy3-conjugated Strepta-
vidin was purchased from Rockland Immunochemicals, Inc., and Alexa 
Fluor 488– and Alexa Fluor 594–coupled secondary antibodies and Hoechst 
33342 were purchased from Invitrogen.
Computer-assisted morphometric analyses. Double immunofluores-
cence stains of ear sections for MECA-32, CD31, and/or LYVE-1 were 
examined  on  an  Axioskop  2  mot  plus  microscope  (Carl  Zeiss,  Inc.), 
equipped with an AxioCam MRc camera and a Plan-APOCHROMAT 
10×/0.45 NA objective (Carl Zeiss, Inc.). Images of three to four individ-
ual fields of view were acquired per section using AxioVision software 4.7.1 
(Carl Zeiss, Inc.). Computer-assisted analyses of digital images were per-
formed using the IP-LABORATORY software (Scanalytics) as previously 
described (Schonthaler et al., 2009). The mean lymphatic and blood vessel 
number per millimeter of epidermal basement membrane and the mean size 
of CD31+/LYVE-1+ lymphatic and of CD31+/LYVE-1 or MECA-32+ 
blood vessels were determined in the area of one ear half between cartilage 
and stratum corneum. The results are expressed as vessel number per milli-
meter of epidermal basement membrane (excluding follicular structures) 
and not as vessel number per area because the formation of inflammatory 
edema (increase in area) would confound the vessel number if it were cal-
culated per area. To quantify CD11b+, CD8+, and BrdU+ cell numbers per 
millimeter of epidermal basement membrane, images of three to four indi-
vidual fields of view were acquired per sample (covering the entire field of 
view between the cartilage backbone and the epidermis).
node was increased as compared with the preinflammatory 
and acute inflammatory state (Fig. 9 A), revealing that the lym-
phatic drainage function is impaired in chronic inflammation. 
Inflammation-induced lymphangiogenesis might therefore 
represent an endogenous counter-regulatory mechanism aimed 
at limiting edema formation and accumulation of inflamma-
tory cells, and therapeutic application of VEGF-C might fur-
ther promote this mechanism. Nevertheless, we cannot fully 
exclude that other VEGF-C activities, including other direct 
effects on the inflamed lymphatic vasculature, are involved in 
its antiinflammatory properties. As an example, the chemokine 
receptor D6 is expressed on lymphatic vessels and sequesters 
several  proinflammatory  chemokines.  D6-deficient  mice 
show histological alterations similar to human psoriasis after 
treatment with phorbol esters (Jamieson et al., 2005). An in-
creased amount of D6 receptor, caused by an overall increase 
in the lymphatic vasculature after VEGFR-3 activation, might 
contribute to the strong improvement of the chronic inflam-
matory skin lesions. That there was no further increase in mea-
sured flow after injection of VEGF-C156S might be the result 
of a limitation of the near-infrared imaging approach, which 
does not specifically measure lymph flow from the ear to the 
draining lymph node. Additionally, constant repetitive injec-
tions into the ear skin, causing local irritations, might disturb 
flow measurements where dye is injected into the same ear. 
Fig. S7 shows a schematic diagram of the proposed model.
Although not assessed in this study, it would be of interest 
to investigate the potential role of lymph node lymphangio-
genesis in the control of inflammation (Angeli et al., 2006; 
Halin et al., 2007). The increased draining capacity and reso-
lution of chronic skin inflammation might be, at least in part, 
mediated by enhanced lymph node lymphangiogenesis in ad-
dition to the increased lymphangiogenesis that we observed 
in the lesional skin itself. In conclusion, our study provides 
the first proof of concept that it might be possible to treat 
chronic inflammatory skin disorders by increasing lymphan-
giogenesis and stimulating lymphatic vessel function, with 
potential implications for the treatment of other chronic in-
flammatory diseases.
MATERIALS AND METHODS
Mouse model of chronic skin inflammation. The generation of K14-
VEGF-A Tg mice that express mouse VEGF-A164 under control of the K14 
promoter, of K14-VEGF-C Tg mice that express human VEGF-C, and of 
K14-VEGF-D Tg mice that express mouse VEGF-D has been described 
previously (Jeltsch et al., 1997; Detmar et al., 1998; Xia et al., 2003; Haiko 
et al., 2008). K14-VEGF-A, K14-VEGF-C, and K14-VEGF-D Tg mice (all 
FVB genetic background) were bred and housed in the animal facility of 
ETH  Zurich.  K14-VEGF-A+C  and  K14-VEGF-A+D  double  Tg  mice 
were generated by crossing homozygous VEGF-A and hemizygous VEGF-C 
or VEGF-D Tg mice, respectively. The mice were genotyped as previously 
described (Jeltsch et al., 1997; Haiko et al., 2008). Untreated FVB wild-type 
mice were used as controls. All experiments were initiated when the 
mice were between 6 and 8 wk of age. Experiments were performed in   
accordance with animal protocol 149/2008 approved by the Kantonales 
Veterinäramt Zürich.
For oxazolone-induced psoriasis-like skin inflammation in the ear 
skin (Kunstfeld et al., 2004), mice were anesthetized by i.p. injection of 
0.2 mg/kg medetomidine and 80 mg/kg ketamine, and 2% oxazolone JEM VOL. 207, September 27, 2010 
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and the fluorescence signal in the lymph node using the near-infrared imag-
ing technique. Fig. S7 shows a schematic diagram of our proposed model of 
inhibition of chronic inflammation by stimulation of lymphangiogenesis via 
VEGFR 3. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20100559/DC1.
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